$CASI News
Last published 8mo ago
- 8mo agoCASICASI Pharmaceuticals Receives the Delisting Decision From the Nasdaq Hearings PanelACCESS NewswireSOUTH SAN FRANCISCO, CA / ACCESS Newswire / February 25, 2026 / CASI Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company focused on developing CID-103, a potential best-in-class, anti-CD38
- 10mo agoCASICASI Pharmaceuticals Announces Approval of Clinical Trial Application by China NMPA for Phase 1 / 2 Study of CID-103 for Renal Allograft Antibody-Mediated Rejection (AMR)ACCESS NewswireCID-103 is a potential best-in-class, anti-CD38 monoclonal antibody; binds to unique CD38 epitopeAMR is a leading cause of kidney transplant loss with no approved treatmentsU.S. IND previously approved by FDA for Phase 1
- 10mo agoCASICASI Pharmaceuticals Receives Extension from Nasdaq to Meet Listing RequirementsACCESS NewswireSOUTH SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / December 23, 2025 / CASI Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company focused on developing CID-103, a potential best-in-class,
- 11mo agoCASICASI Pharmaceuticals Announces Up to $20 Million Convertible Note FinancingACCESS Newswire- Investment to Fund Phase 1 Study in Renal Allograft Antibody-Mediated Rejection in China SOUTH SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / December 11, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI, the ",
- 11mo agoCASICASI Pharmaceuticals Announces Results from CID-103 Immune Thrombocytopenia Study at the 67th American Society of Hematology (ASH) Annual MeetingACCESS NewswireSOUTH SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / December 8, 2025 / CASI Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company developing CID-103, a potentially best-in-class, anti-CD38
- 11mo agoCASICASI Pharmaceuticals Announces Changes in Board GovernanceACCESS NewswireJames Huang appointed as Non-Executive Chairman of CASI Board of Directors SOUTH SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / November 19, 2025 / CASI Pharmaceuticals, Inc. , a clinical-stage
- 12mo agoCASICASI Pharmaceuticals Announces Third Quarter 2025 Business and Financial ResultsACCESS NewswireSOUTH SAN FRANCISCO, CA / ACCESS Newswire / November 14, 2025 / CASI Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company focused on the development of CID-103, a potential best-in-class,
- 1y agoCASICASI Pharmaceuticals Receives and Appeals Delisting Determination from NASDAQACCESS NewswireSOUTH SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / November 10, 2025 / CASI Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company focused on developing CID-103, a potential best-in-class,
- 1y agoCASICASI Pharmaceuticals to Participate at Guggenheim Healthcare Innovation ConferenceACCESS NewswireSOUTH SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / November 4, 2025 / CASI Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company focused on developing CID-103, a potential best-in-class,
- 1y agoCASICASI Pharmaceuticals Announces Upcoming Presentation of Clinical Results for CID-103 at the 67th American Society of Hematology (ASH) Annual MeetingACCESS Newswire- CID-103 is a potential best-in-class, anti-CD38 monoclonal antibody- Phase 1 dose escalation study in Immune Thrombocytopenia results and update SOUTH SAN FRANCISCO, CA / ACCESS Newswire / November 3, 2025 / CASI
- 1y agoCASICASI Pharmaceuticals Appoints James Huang to Board of DirectorsACCESS Newswire- Industry veteran brings over 35 years of biotech experience as a successful entrepreneur and investor- Operating experience to significantly enhance development program of CID-103
- 1y agoCASICASI Pharmaceuticals Announces Safety Monitoring Committee Recommendation to Escalate CID-103 Dose to Next Cohort in Phase 1 Immune Thrombocytopenia (ITP) StudyACCESS Newswire- CID-103 is a potential best-in-class, clinical stage anti-CD38 monoclonal antibody- Safety profile observed in first four dose cohorts supports continued development- No serious adverse events or dose-limiting
- 1y agoCASICASI Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment ConferenceACCESS NewswireSOUTH SAN FRANCISCO, CA / ACCESS Newswire / September 3, 2025 / CASI Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with organ
- 1y agoCASICASI Pharmaceuticals Appoints Barbara Krebs-Pohl, PhD to Board of DirectorsACCESS Newswire- Industry veteran brings extensive senior level leadership and expertise in biologics development, strategic partnerships, mergers and acquisitions across biotech and large pharma organizations- Operating experience to
- 1y agoCASICASI Pharmaceuticals Announces Second Quarter 2025 Business and Financial ResultsACCESS NewswireSOUTH SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / August 29, 2025 / CASI Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with
- 1y agoCASICASI Pharmaceuticals to Participate at Cantor Global Healthcare Conference 2025ACCESS NewswireSAN FRANCISCO, CA / ACCESS Newswire / August 28, 2025 / CASI Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with organ transplant
- 1y agoCASICASI Pharmaceuticals Announces FDA Clearance of IND Application for CID-103 in Renal Allograft Antibody-Mediated Rejection (AMR)ACCESS NewswireCID-103 is a potential best-in-class, anti-CD38 monoclonal antibody; binds to unique CD38 epitopePhase 1 study in adults with active and chronic active renal allograft AMR planned to initiateAMR is a leading cause of
- 1y agoCASICASI Pharmaceuticals Appoints David Cory as Chief Executive Officer to Lead U.S. Company Focused on Clinical Development of CID-103, a Potential Best in Class Anti-CD38 ProgramACCESS Newswire-- David Cory is an industry veteran, bringing more than 30 years of operational experience, in private and public, emerging-stage biotech and large pharma companies with an established track record of building and
- 1y agoCASICASI Pharmaceuticals Provides Business and Clinical UpdateACCESS NewswireBEIJING, CHINA / ACCESS Newswire / May 19, 2025 / CASI Pharmaceuticals, Inc. , , a Cayman incorporated biopharmaceutical company focused on developing and
- 1y agoCASICASI Pharmaceuticals Announces First Quarter 2025 Business and Financial ResultsACCESS NewswireBEIJING, CN / ACCESS Newswire / May 16, 2025 / CASI Pharmaceuticals, Inc. , , a Cayman incorporated biopharmaceutical company focused on developing and
- 1y agoCASICASI Pharmaceuticals Enters Into Definitive Agreement for the Divestiture of Assets in ChinaACCESS NewswireBEIJING, CHINA / ACCESS Newswire / May 12, 2025 / CASI Pharmaceuticals, Inc. , , a Cayman incorporated biopharmaceutical company focused on developing and
- 1y agoCASICASI Pharmaceuticals Receives Nasdaq Deficiency Notice Regarding Minimum Market Value RequirementACCESS NewswireBEIJING, CHINA / ACCESS Newswire / May 7, 2025 / CASI Pharmaceuticals, Inc. , , a Cayman incorporated biopharmaceutical company focused on developing and
- 1y agoCASICASI Pharmaceuticals Announces Receipt of An Updated Non-Binding Proposal to Acquire Entire China Business of the CompanyACCESS NewswireBEIJING, CN / ACCESS Newswire / April 3, 2025 / CASI Pharmaceuticals, Inc. ), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative
- 1y agoCASICASI Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Business and Financial ResultsACCESS NewswireBEIJING, CHINA / ACCESS Newswire / March 31, 2025 / CASI Pharmaceuticals, Inc. , , a Cayman incorporated biopharmaceutical company focused on developing and
- 1y agoCASICASI Announces First Patient Dosed in Phase 1/2 Clinical Trial of CID-103 in Immune ThrombocytopeniaACCESS NewswireBEIJING, CHINA / ACCESSWIRE / January 6, 2025 / CASI Pharmaceuticals, Inc. , a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and pharmaceutical
- 1y agoCASICASI Pharmaceuticals Announces Third Quarter 2024 Business and Financial ResultsACCESS NewswireBEIJING, CHINA / ACCESSWIRE / November 15, 2024 / CASI Pharmaceuticals, Inc. , a Cayman incorporated biopharmaceutical company specializing in the development
- 2y agoCASICASI Pharmaceuticals Receives CTA Approval From China's NMPA for CID-103 in Immune ThrombocytopeniaACCESS NewswireBEIJING, CHINA / ACCESSWIRE / October 24, 2024 / CASI Pharmaceuticals, Inc. , a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and pharmaceutical
- 2y agoCASICASI PHARMACEUTICALS TO PARTICIPATE IN THE 2024 H.C. WAINWRIGHT GLOBAL INVESTMENT CONFERENCEPR NewswireCASI Pharmaceuticals, Inc. (Nasdaq: CASI) ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company specializing in the development...
- 2y agoCASICASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2024 BUSINESS AND FINANCIAL RESULTSPR NewswireCASI Pharmaceuticals, Inc. (Nasdaq: CASI) ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company specializing in the development...
- 2y agoAGENAMGNCASILGND+8Ligand Reports Second Quarter 2024 Financial ResultsBusiness WireConference call at 4:30 p.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and six months ended June 30, 2024, and provided an operating forecast
- 2y agoCASICASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTASPR NewswireCASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative...
- 2y agoCASICASI Pharmaceuticals announces appointment of Daniel Lang, MD as CFO and SVPPR NewswireCASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative...
- 2y agoCASICASI Pharmaceuticals Announces Plan To Submit IND Application For CID-103, an Anti-CD 38 Antibody in Antibody-Mediated Rejection, and Receipt of a Non-Binding Proposal to Acquire Entire China Business of the CompanyPR NewswireCASI Pharmaceuticals, Inc. (Nasdaq: CASI) ("CASI" or the "Company"), a biopharmaceutical company specializing in the development and...
- 2y agoCASICASI Pharmaceuticals Announces $15 Million Private Placement Financing by Venrock Healthcare Capital Partners, Foresite Capital, Panacea Venture and Dr. Wei-Wu HePR NewswireCASI Pharmaceuticals, Inc. (Nasdaq: CASI) ("CASI" or the "Company"), a biopharmaceutical company specializing in the development and...
- 2y agoCASICASI Pharmaceuticals Receives FDA Clearance On The Investigational New Drug (IND) Application For CID-103 In Immune Thrombocytopenia (ITP)PR NewswireCASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company specializing in the development and commercialization of innovative...
- 2y agoCASICASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2024 BUSINESS AND FINANCIAL RESULTSPR NewswireCASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative...
- 2y agoAMGNCASIJAZZLGND+3Ligand Reports First Quarter 2024 Financial ResultsBusiness WireConference Call Begins at 4:30 p.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three months ended March 31, 2024, and provided an operating forecast
- 2y agoCASICASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTASPR NewswireCASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative...
- 2y agoCASICASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2023 BUSINESS AND FINANCIAL RESULTSPR NewswireCASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative...
- 2y agoCASIBINVCASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma In ChinaPR NewswireCASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company specializing in the development and commercialization of innovative...
- 2y agoCASICASI PHARMACEUTICALS ANNOUNCES FIRST DOSING OF FOLOTYN® IN CHINAPR NewswireCASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company specializing in the development and commercialization of innovative...
- 2y agoCASICASI PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2023 BUSINESS AND FINANCIAL UPDATESPR NewswireCASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and...
- 3y agoCASICASI PHARMACEUTICALS ANNOUNCES MARKET APPROVAL OF CNCT19 BY CHINA NMPAPR NewswireCASI Pharmaceuticals Inc. (Nasdaq: CASI), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and...
- 3y agoCASICASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2023 BUSINESS AND FINANCIAL UPDATESPR NewswireBEIJING, Aug. 11, 2023 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported
- 3y agoCASICleave Therapeutics Announces Acquisition of Clinical and Preclinical AssetsBusiness Wire~ CASI Pharmaceuticals acquires global rights to CB-5339, a clinical stage VCP/p97 inhibitor in development for oncology indications ~ Eikon Therapeutics acquires pre-clinical assets spanning multiple targets Cleave
- 3y agoCASICASI Pharmaceuticals Acquires Global Intellectual Property Rights to Cleave Therapeutics' VCP/P97 Inhibitor CB-5339PR NewswireBEIJING, July 20, 2023 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced
- 3y agoCASICASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2023 FINANCIAL RESULTSPR NewswireBEIJING, May 17, 2023 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a Cayman Islands incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical
- 3y agoCASICASI Pharmaceuticals Files Annual Report on Form 20-F for Fiscal Year 2022PR NewswireBEIJING, April 26, 2023 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ:CASI) ("CASI" or the "Company"), a biopharmaceutical company focused on developing and commercializing innovative therapeutics
- 3y agoCASICASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2022 FINANCIAL RESULTSPR NewswireBEIJING, April 26, 2023 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical
- 3y agoCASICASI PHARMACEUTICALS COMPLETES REDOMICILIATION MERGERPR NewswireBEIJING, March 21, 2023 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ:CASI) ("CASI" or the "Company"), a biopharmaceutical company focused on developing and commercializing innovative therapeutics